var data={"title":"Cetuximab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cetuximab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5860?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cetuximab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cetuximab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708650\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiopulmonary arrest:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cardiopulmonary arrest and/or sudden death occurred in 2% of patients with squamous cell carcinoma of the head and neck treated with radiation and cetuximab and in 3% of patients with squamous cell carcinoma of the head and neck treated with European Union (EU)&ndash;approved cetuximab in combination with platinum-based therapy with 5-fluorouracil. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after cetuximab administration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infusion reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious infusion reactions occurred with the administration of cetuximab in approximately 3% of patients in clinical trials, with fatal outcomes reported in fewer than 1 in 1,000. Immediately interrupt and permanently discontinue cetuximab infusion for serious infusion reactions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149013\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Erbitux</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1995494\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Erbitux</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149033\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149015\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedicate with an H<sub>1</sub> antagonist (eg, diphenhydramine) IV 30 to 60 minutes prior to the first dose; premedication for subsequent doses is based on clinical judgment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic, KRAS wild-type (without mutation):</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial loading dose: 400 mg/m<sup>2</sup> infused over 120 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maintenance dose: 250 mg/m<sup>2</sup> infused over 60 minutes weekly until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> If given in combination with FOLFIRI (irinotecan, fluorouracil, and leucovorin), complete cetuximab infusion 1 hour prior to FOLFIRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer (squamous cell):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial loading dose: 400 mg/m<sup>2</sup> infused over 120 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maintenance dose: 250 mg/m<sup>2</sup> infused over 60 minutes weekly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> If given in combination with radiation therapy, administer loading dose 1 week prior to initiation of radiation course; weekly maintenance dose should be completed 1 hour prior to radiation for the duration of radiation therapy (6 to 7 weeks). If given in combination with chemotherapy, administer loading dose on the day of initiation of platinum and fluorouracil-based chemotherapy, cetuximab infusion should be completed 1 hour prior to initiation of chemotherapy; weekly maintenance dose should be completed 1 hour prior to chemotherapy; continue until disease progression or unacceptable toxicity. Monotherapy weekly doses should be continued until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Colorectal cancer, advanced, biweekly administration (off-label dosing):</b> IV: 500 mg/m<sup>2</sup> every 2 weeks (initial dose infused over 120 minutes, subsequent doses infused over 60 minutes) in combination with irinotecan (Pfeiffer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Non-small cell lung cancer (NSCLC), EGFR-expressing, advanced (off-label use):</b> IV: Initial loading dose: 400 mg/m<sup>2</sup>, followed by maintenance dose: 250 mg/m<sup>2</sup> weekly in combination with cisplatin and vinorelbine for up to 6 cycles, then as monotherapy until disease progression or unacceptable toxicity (Pirker 2009; Pirker 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Squamous cell skin cancer, unresectable (off-label use):</b> IV:  Initial loading dose: 400 mg/m<sup>2</sup>, followed by maintenance dose: 250 mg/m<sup>2</sup> weekly until disease progression (Maubec 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149016\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682571\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682572\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149034\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion reactions, grade 1 or 2 and nonserious grade 3: Reduce the infusion rate by 50% and continue to use prophylactic antihistamines </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infusion reactions, severe: Immediately and permanently discontinue treatment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pulmonary toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acute onset or worsening pulmonary symptoms: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Interstitial lung disease: Permanently discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Skin toxicity, mild to moderate: No dosage modification required </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acneiform rash, severe (grade 3 or 4):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First occurrence: Delay cetuximab infusion 1 to 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">If improvement, continue at 250 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">If no improvement, discontinue therapy </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Second occurrence: Delay cetuximab infusion 1 to 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">If improvement, continue at reduced dose of 200 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">If no improvement, discontinue therapy </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Third occurrence: Delay cetuximab infusion 1 to 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">If improvement, continue at reduced dose of 150 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">If no improvement, discontinue therapy </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fourth occurrence: Discontinue therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148996\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erbitux: 100 mg/50 mL (50 mL); 200 mg/100 mL (100 mL) [contains galactose-alpha-1,3-galactose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148983\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148998\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer via IV infusion; loading dose over 2 hours, weekly maintenance dose over 1 hour. Do not administer as IV push or bolus. Do not shake or dilute. Administer via infusion pump or syringe pump. Following the infusion, an observation period (1 hour) is recommended; longer observation time (following an infusion reaction) may be required. Premedication with an H<sub>1</sub> antagonist prior to the initial dose is recommended. The maximum infusion rate is 10 mg/minute. Administer through a low protein-binding 0.22 micrometer in-line filter.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For biweekly administration (off-label frequency and dose), the initial dose was infused over 120 minutes and subsequent doses infused over 60 minutes (Pfeiffer 2007; Pfeiffer 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148997\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic:</b> Treatment of <i>KRAS</i> wild-type (without mutation), epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer as determined by approved tests (in combination with FOLFIRI [irinotecan, fluorouracil, and leucovorin] as first-line treatment, in combination with irinotecan [in patients refractory to irinotecan-based chemotherapy], or as a single agent in patients who have failed irinotecan- and oxaliplatin-based chemotherapy or who are intolerant to irinotecan).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitation of use: Cetuximab is not indicated for the treatment of <i>RAS</i>-mutant colorectal cancer or when results of the <i>RAS</i> mutation tests are unknown. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Head and neck cancer, squamous cell:</b> Treatment of squamous cell cancer of the head and neck (as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475343\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Non-small cell lung cancer, EGFR-expressing, advanced; Squamous cell skin cancer, unresectable</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110716\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cetuximab may be confused with bevacizumab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148988\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fatigue (91%), malaise (&le;73%), pain (59%), peripheral sensory neuropathy (45%; grades 3/4: 1%), headache (19% to 38%), insomnia (27%), confusion (18%), chills (&le;16%), rigors (&le;16%), anxiety (14%), depression (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Desquamation (95%), acneiform eruption (15% to 88%; grades 3/4: 1% to 18%), radiodermatitis (86%), xeroderma (14% to 57%), pruritus (14% to 47%), skin rash (28% to 44%), changes in nails (31%), acne vulgaris (14% to 22%), paronychia (20%), palmar-plantar erythrodysesthesia (19%), skin fissure (19%), alopecia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight loss (15% to 84%), hypomagnesemia (6% to 55%), dehydration (13% to 25%), hypocalcemia (12%), hypokalemia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (19% to 72%), nausea (49% to 64%), abdominal pain (59%), constipation (53%), vomiting (40%), stomatitis (31% to 32%), anorexia (25% to 30%), dyspepsia (14% to 16%), xerostomia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia (49%; grades 3/4: 31%), leukopenia (grades 3/4: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum ALT (43%), increased serum AST (38%), increased serum alkaline phosphatase (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (13% to 44%), infection without neutropenia (38%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Application site reaction (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (&le;73%), ostealgia (15%), arthralgia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis (10% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (49%), cough (30%), pharyngitis (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (22% to 29%), infusion related reaction (10% to 18%; grades 3/4: 2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Cardiorespiratory arrest (2% to 3%), ischemic heart disease (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Hypertrichosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dysgeusia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Antibody development (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Sepsis (1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Renal failure (1%: colorectal cancer patients; frequency not defined in other populations)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abscess, aseptic meningitis, blepharitis, bronchospasm, bullous pemphigoid, cardiac arrhythmia, cellulitis, cheilitis, corneal ulcer, electrolyte disturbance, hoarseness, hypotension, interstitial pulmonary disease, keratitis, loss of consciousness, mucosal inflammation, myocardial infarction, pulmonary embolism, shock, skin infection, Stevens-Johnson syndrome, stridor, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149001\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Known severe hypersensitivity to cetuximab or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148986\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiopulmonary arrest: <b>[US Boxed Warning]: In patients with squamous cell head and neck cancer, cardiopulmonary arrest and/or sudden death has occurred in 2% of patients receiving radiation therapy in combination with cetuximab and in 3% of patients receiving combination chemotherapy (platinum and fluorouracil-based) with cetuximab. Closely monitor serum electrolytes (magnesium, potassium, calcium) during and after cetuximab treatment</b> (monitor for at least 8 weeks after treatment). Use with caution in patients with a history of coronary artery disease, heart failure, and arrhythmias; fatalities have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic toxicity: Acneiform rash has been reported in 76% to 88% of patients (severe in 1% to 17%), usually developing within the first 2 weeks of therapy; may require dose modification; generally resolved after discontinuation in most patients, although persisted beyond 28 days in some patients. Acneiform rash should be treated with topical and/or oral antibiotics; topical corticosteroids are not recommended. In colorectal cancer, the presence of acneiform rash correlates with treatment response and prolonged survival (Cunningham, 2004). Life-threatening and fatal bullous mucocutaneous disease (with blisters, erosions, and skin sloughing) has been observed with cetuximab; etiology is not determined; may be due to epidermal growth factor receptor (EGFR) inhibition or to idiosyncratic immune-related effects (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis). Other dermatologic toxicities, including dry skin, fissures, hypertrichosis, paronychial inflammation, and skin infections, have been reported; related ocular toxicities (blepharitis, conjunctivitis, keratitis, ulcerative keratitis with decreased visual acuity) may also occur. Monitor closely for dermatologic toxicities and potential infectious sequelae. Sunlight may exacerbate skin reactions (limit sun exposure).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte abnormality: Hypomagnesemia is common (may be severe); the onset of electrolyte disturbance may occur within days to months after initiation of treatment; monitor magnesium, calcium, and potassium during treatment and for at least 8 weeks after completion. May require electrolyte replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion reactions: <b>[US Boxed Warning]: In clinical trials, serious infusion reactions have been reported in approximately 3% of patients; fatal outcome has been reported rarely (less than 1 in 1,000); interrupt infusion promptly and permanently discontinue for serious infusion reactions.</b> Reactions have included airway obstruction (bronchospasm, stridor, hoarseness), hypotension, loss of consciousness, shock, myocardial infarction (MI), and/or cardiac arrest. Premedicate with anintravenous (IV) H<sub>1</sub> antagonist 30 to 60 minutes prior to the first dose; premedication for subsequent doses is based on clinical judgment and with consideration of prior reaction to the initial infusion. The use of nebulized albuterol-based premedication to prevent infusion reaction has been reported (Tra, 2008). Approximately 90% of reactions occur with the first infusion despite the use of prophylactic antihistamines. Immediate treatment for anaphylactic/anaphylactoid reactions should be available during administration. The manufacturer recommends monitoring patients for at least 1 hour following completion of infusion, or longer if a reaction occurs. Mild to moderate infusion reactions (chills, fever, dyspnea) are managed by slowing the infusion rate (by 50%) and administering antihistamines. Patients with preexisting IgE antibody against cetuximab (specific for galactose-&alpha;-1,3-galactose) are reported to have a higher incidence of severe hypersensitivity reaction. Severe hypersensitivity reaction has been reported more frequently in patients living in the middle south area of the United States, including North Carolina and Tennessee (Chung, 2008; O&rsquo;Neil, 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Interstitial lung disease: Has been reported; use with caution in patients with preexisting lung disease. Interrupt treatment for acute onset or worsening of pulmonary symptoms. Permanently discontinue with confirmed interstitial lung disease. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Colorectal cancer and <i>RAS</i> mutation status: Cetuximab is only indicated for patients with EGFR-expressing metastatic colorectal cancer without <i>RAS</i> (<i>KRAS</i> or <i>NRAS</i>) mutations. Determine  <i>RAS</i> mutation status prior to treatment (with an approved test). Patients with a codon 12 and 13 (exon 2), codon 59 and 61 (exon 3), and codon 117 and 146 (exon 4) <i>RAS</i> mutation are unlikely to benefit from EGFR inhibitor therapy (while experiencing toxicities) and should not receive cetuximab treatment; cetuximab is not effective for colorectal cancer with <i>RAS</i> mutations. Cetuximab is also reported to be ineffective in patients with <i>BRAF</i> V600E mutation (Di Nicolantonio, 2008). The American Society of Clinical Oncology (ASCO) provisional clinical opinion (Allegra, 2009) recommends genotyping tumor tissue for KRAS mutation in all patients with metastatic colorectal cancer (genotyping may be done on archived specimens).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; EGFR expression testing: In trials for colorectal cancer, evidence of EGFR expression was required, although the response rate did not correlate with either the percentage of cells positive for EGFR or the intensity of expression. EGFR expression has been detected in nearly all patients with head and neck cancer; therefore, laboratory evidence of EGFR expression is not necessary for head and neck cancers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Combination with cisplatin and radiation therapy: In a study of radiation therapy <b>and</b> cisplatin with or without cetuximab in patients with squamous cell head and neck cancer, an increase in the incidence of adverse reactions (eg, grade 3/4 mucositis, radiation recall, acneiform rash, electrolyte abnormalities, and cardiac events including ischemia) was noted in patients receiving cetuximab, including fatal reactions. There was no improvement in the primary end point of progression-free survival.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anti-cetuximab antibodies: Non-neutralizing anti-cetuximab antibodies were detected in 5% of evaluable patients. Relationship between the appearance of antibodies and the safety or antitumor activity of the molecule is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299006\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148990\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9209&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148992\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149004\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Human IgG is known to cross the placenta. Because cetuximab inhibits epidermal growth factor (EGF), a component of fetal development, adverse effects on pregnancy would be expected. The manufacturer recommends that males and females use effective contraception during therapy and for 6 months following the last dose of cetuximab. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149005\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cetuximab is excreted in breast milk. IgG antibodies can be detected in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends that the decision to discontinue cetuximab or discontinue breast-feeding should take into account the benefits of treatment to the mother. If breast-feeding is interrupted for cetuximab treatment, based on the half-life, breast-feeding should not be resumed for at least 60 days following the last cetuximab dose. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148994\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs during infusion and observe for at least 1 hour postinfusion. Patients developing dermatologic toxicities should be monitored for the development of complications. Periodic monitoring of serum magnesium, calcium, and potassium are recommended to continue over an interval consistent with the half-life (8 weeks); monitor closely (during and after treatment) for cetuximab plus radiation therapy.  <i>KRAS</i> genotyping of tumor tissue in patients with colorectal cancer </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148985\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Recombinant human/mouse chimeric monoclonal antibody which binds specifically to the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands. Binding to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. EGFR signal transduction results in <i>RAS</i> wild-type activation; cells with <i>RAS</i> mutations appear to be unaffected by EGFR inhibition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149000\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~2 to 3 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~112 hours (range: 63 to 230 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4370503\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Erbitux Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/50 mL (50 mL): $727.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $1,455.65</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149006\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cetuxim (BD);</li>\n      <li>Erbitux (AE, AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SE, SG, SI, SK, SV, TH, TR, TW, UA, VE, VN, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allegra CJ, Jessup JM, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Provisional Clinical Opinion: Testing for <i>KRAS</i> Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy,&rdquo; <i>J Clin Oncol</i>, 2009, 27(12):2091-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/19188670/pubmed\" target=\"_blank\" id=\"19188670\">19188670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baselga J, &ldquo;The EGFR as a Target for Anticancer Therapy - Focus on Cetuximab,&rdquo; <i>Eur J Cancer</i>, 2001, 37(Suppl 4):16-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonner JA, Harari PM, Giralt J, et al, &ldquo;Radiotherapy Plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck,&rdquo; <i>N Engl J Med</i>, 2006, 354(6):567-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/16467544/pubmed\" target=\"_blank\" id=\"16467544\">16467544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung CH, Mirakhur B, Chan E, et al, &ldquo;Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-alpha-1,3-galactose,&rdquo; <i>N Engl J Med</i>, 2008, 358(11):1109-17<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/18337601/pubmed\" target=\"_blank\" id=\"18337601\">18337601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham D, Humblet Y, Siena S, et al, &ldquo;Cetuximab Monotherapy and Cetuximab Plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,&rdquo; <i>N Engl J Med</i>, 2004, 351(4):337-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/15269313/pubmed\" target=\"_blank\" id=\"15269313\">15269313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Nicolantonio F, Martini M, Molinari F, et al, &ldquo;Wild-type BRAF is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer,&rdquo; <i>J Clin Oncol</i>, 2008, 26(35):5705-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/19001320/pubmed\" target=\"_blank\" id=\"19001320\">19001320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erbitux (cetuximab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feinstein TM, Gibson MK, and Argiris A, &ldquo;Cetuximab-Induced Aseptic Meningitis,&rdquo; <i>Ann Oncol</i>, 2009, 20(9):1609-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/19643807/pubmed\" target=\"_blank\" id=\"19643807\">19643807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonker DJ, O&rsquo;Callaghan CJ, Karapetis CS, et al, &ldquo;Cetuximab for the Treatment of Colorectal Cancer,&rdquo; <i>N Engl J Med</i>, 2007, 357(20):2040-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/18003960/pubmed\" target=\"_blank\" id=\"18003960\">18003960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karapetis CS, Khambata-Ford S, Jonker DJ, et al, &ldquo;K-ras Mutations and Benefit From Cetuximab in Advanced Colorectal Cancer,&rdquo; <i>N Engl J Med</i>, 2008, 359(17):1757-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/18946061/pubmed\" target=\"_blank\" id=\"18946061\">18946061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21810686\"></a>Maubec E, Petrow P, Scheer-Senyarich I, et al, &ldquo;Phase II Study of Cetuximab as First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin,&rdquo; <i>J Clin Oncol</i>, 2011, 29(25):3419-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/21810686/pubmed\" target=\"_blank\" id=\"21810686\">21810686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Neil BH, Allen R, Spigel DR, et al, &ldquo;High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History,&rdquo; <i>J Clin Oncol</i>, 2007, 25(24):3644-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/17704414/pubmed\" target=\"_blank\" id=\"17704414\">17704414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfeiffer P, Bjerregarrd JK, Qvortrup C, et al, &ldquo;Simplification of Cetuximab (Cet) Administration: Double Dose Every Second Week as a 60 Minute Infusion,&rdquo; <i>J Clin Oncol</i>, 2007, 25(18S):4133 [abstract 4133 from 2007 ASCO Annual Meeting Proceedings, Part I].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfeiffer P, Nielsen D, Bjerregaard J, et al, &ldquo;Biweekly Cetuximab and Irinotecan as Third-Line Therapy in Patients With Advanced Colorectal Cancer After Failure to Irinotecan, Oxaliplatin and 5-Fluorouracil,&rdquo; <i>Ann Oncol</i>, 2008, 19(6):1141-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/18281264/pubmed\" target=\"_blank\" id=\"18281264\">18281264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pirker R, Pereira JR, Szczesna A, et al, &ldquo;Cetuximab Plus Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial,&rdquo; <i>Lancet</i>, 2009, 373(9674):1525-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/19410716/pubmed\" target=\"_blank\" id=\"19410716\">19410716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22056021\"></a>Pirker R, Pereira JR, von Pawel J, et al, &ldquo;EGFR Expression as a Predictor of Survival for First-Line Chemotherapy Plus Cetuximab in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Data From the Phase 3 FLEX Study,&rdquo; <i>Lancet Oncol</i>, 2012, 13(1):33-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/22056021/pubmed\" target=\"_blank\" id=\"22056021\">22056021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tra F, Fesen MR, Pianalto M, et al, &ldquo;Albuterol-Based Premedication Therapy for the Prevention of Cetuximab Infusion-Related Reactions,&rdquo; <i>J Clin Oncol</i>, 2008, 26(Supp):17040 [abstract 17040 from ASCO 2008 Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Cutsem E, K&ouml;hne CH, L&aacute;ng I, et al, &ldquo;Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status,&rdquo; <i>J Clin Oncol</i>, 2011, 29(15):2011-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/21502544/pubmed\" target=\"_blank\" id=\"21502544\">21502544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Cutsem E, Lang, I, D&rsquo;haens G, et al, &ldquo;<i>KRAS</i> Status and Efficacy in the First-Line Treatment of Patients With Metastatic Colorectal Cancer (mCRC) Treated With FOLFIRI With or Without Cetuximab: The CRYSTAL Experience,&rdquo; <i>J Clin Oncol</i>, 2008, 26(Supp):2 [abstract 2 from ASCO 2008 Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. <i>J Clin Oncol</i>. 2012;30(23):2861-2868.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/22753904/pubmed\" target=\"_blank\" id=\"22753904\">22753904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vermorken JB, Mesia R, Rivera F, et al, &quot;Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer,&quot; <i>N Engl J Med</i>, 2008, 359(11):1116-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cetuximab-drug-information/abstract-text/18784101/pubmed\" target=\"_blank\" id=\"18784101\">18784101</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9209 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708650\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F149013\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F1995494\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F149033\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F149015\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F149016\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682571\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682572\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F149034\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F148996\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F148983\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F148998\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F148997\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475343\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2110716\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F148988\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F149001\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F148986\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299006\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F148990\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F148992\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F149004\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F149005\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F148994\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F148985\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F149000\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4370503\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F149006\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9209|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cetuximab-patient-drug-information\" class=\"drug drug_patient\">Cetuximab: Patient drug information</a></li></ul></div></div>","javascript":null}